Results 21 to 30 of about 152,178 (350)

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

British medical journal, 2023
Objective To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic ...
F. Ma, Min Yan, Wei Li, Q. Ouyang, Z. Tong, Y. Teng, Yongsheng Wang, Shusen Wang, C. Geng, Ting Luo, Jincai Zhong, Qingyuan Zhang, Qiang Liu, Xiaohua Zeng, T. Sun, Qinguo Mo, Hu Liu, Ying Cheng, Jing Cheng, Xiaojian Wang, J. Nie, Jin Yang, Xin-hong Wu, Xinshuai Wang, Huiping Li, Changsheng Ye, Fangli Dong, Shuchao Wu, Xiaoyu Zhu, Binghe Xu   +29 more
semanticscholar   +1 more source

[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

EJNMMI Radiopharmacy and Chemistry, 2023
Background Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain.
Misaki Kondo, Zhongli Cai, Conrad Chan, Nubaira Forkan, Raymond M. Reilly   +4 more
doaj   +1 more source

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

JAMA Oncology, 2022
Key Points Question Can tucatinib, trastuzumab, and capecitabine provide systemic and intracranial benefit for patients with ERBB2 (HER2)-positive metastatic breast cancer and brain metastases?
N. Lin, R. Murthy, V. Abramson, C. Anders, T. Bachelot, P. Bedard, V. Borges, D. Cameron, L. Carey, A. J. Chien, G. Curigliano, M. DiGiovanna, K. Gelmon, G. Hortobagyi, S. Hurvitz, I. Krop, S. Loi, S. Loibl, V. Mueller, Mafalda Oliveira, E. Paplomata, M. Pegram, D. Slamon, A. Zelnak, J. Ramos, W. Feng, Eric P. Winer   +26 more
semanticscholar   +1 more source

Current perspective – Trastuzumab [PDF]

European Journal of Cancer, 2009
This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast cancer.
Hall, P.S., Cameron, D.A.
openaire   +3 more sources

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) [PDF]

, 2005
Background: The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC).
Baselga J, Baselga J, Cobleigh MA, Gelmon KA, Kaplan EL, Marty M, Robert NJ, Slamon D, Tripathy D, Vogel CL   +9 more
core   +1 more source

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Scientific Reports, 2021
Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal ...
Nagarajan Vinod, Jae Hyung Kim, Seungbum Choi, Ilhan Lim   +3 more
doaj   +1 more source

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. [PDF]

, 2012
Limited data exist regarding treatment patterns and outcomes in elderly patients with HER2-positive metastatic breast cancer (MBC). registHER is an observational study of patients (N = 1,001) with HER2-positive MBC diagnosed within 6 months of enrollment
Brufsky, Adam M, Feng, Shibao, Kaufman, Peter A, Mayer, Musa, Quah, Cheng S, Rugo, Hope S, Tripathy, Debu, Wang, Lisa I, Yardley, Denise A, Yood, Marianne Ulcickas   +9 more
core   +1 more source

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

New England Journal of Medicine, 2020
BACKGROUND Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
K. Shitara, Y. Bang, S. Iwasa, N. Sugimoto, M. Ryu, D. Sakai, H. Chung, H. Kawakami, H. Yabusaki, Jeeyun Lee, K. Saito, Y. Kawaguchi, T. Kamio, A. Kojima, M. Sugihara, K. Yamaguchi   +15 more
semanticscholar   +1 more source

Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells

BMC Cancer, 2023
Background Trastuzumab is the only approved target agent for the first-line treatment of human epidermal growth factor receptor-2 (HER-2) positive gastric cancer; however, trastuzumab resistance is a major problem in clinical practice.
Yuna Kim, Yoo Jin Bae, Jie-Hyun Kim, Hyunki Kim, Su-Jin Shin, Da Hyun Jung, Hyojin Park   +6 more
doaj   +1 more source

Trastuzumab

Women's Health, 2005
Breast cancer is a heterogenous disease with several clinical and biologic subtypes. Human epidermal growth factor receptor 2 (HER 2) is overexpressed in approximately 20% of breast cancers. This overexpression is usually due to HER 2 gene amplification, and results in a more aggressive tumor with a worse prognosis.
Ian E, Smith, Susan G, Cross
openaire   +2 more sources